Wave Life Sciences, Inc. (WVE) stock
Close on Nov 12, 2026Market cap $622.26MP/E –Yield –
Wave Life Sciences, Inc. reported revenue of $70.92M for the twelve months to Sep 30, 2026. Free cash flow was -$208.39M. At the latest close the market valued the company at $622.26M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $622.26M
- P/E ratio
- –
- Price to sales
- 8.77
- Price to book
- 1.55
- Dividend yield
- –
- Free cash flow yield
- -33.49%
Fundamentals
- Revenue
- $70.92M
- Net income
- -$210.53M
- EPS, diluted
- -$1.06
- Free cash flow
- -$208.39M
- Book value per share
- $1.97
- Diluted shares
- 204M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $3.42
- Open
- $3.45
- Day's range
- $3.15 – $3.53
- Volume
- 2,473,304
- Average volume (20 days)
- 2,980,528
- Beta (5 years)
- 1.31
- 52-week range
- $3.04 – $21.73
- RSI (14 days)
- 38.3
- Volatility (1 year)
- 167.6%
- Relative volume
- 0.81×
- WACC
- 11.4%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | WVE | S&P 500 | Difference | WVE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.8% | -2.7% | −1.1 pts | ||
| 3 months | -39.8% | -1.7% | −38.0 pts | ||
| Year to date | -81.4% | +11.9% | −93.3 pts | ||
| 1 year | -54.6% | +12.0% | −66.6 pts | ||
| 3 years | -39.9% | +78.2% | −118.1 pts | -15.6% | +21.2% |
| 5 years | -32.3% | +73.2% | −105.5 pts | -7.5% | +11.6% |
| 10 years | -91.4% | +309.6% | −401.0 pts | -21.7% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Wave Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
About Wave Life Sciences
Pharmaceutical Preparations
Wave Life Sciences is a clinical-stage biotechnology company developing ribonucleic acid (RNA) medicines to treat rare and prevalent human disorders. Utilizing its proprietary PRISM platform, the company designs stereopure oligonucleotides across modalities including RNA interference, RNA editing, antisense silencing, and splicing. Its therapeutic pipeline focuses on clinical candidates for obesity, alpha-1 antitrypsin deficiency, and PNPLA3-related liver disease, alongside clinical programs targeting Duchenne muscular dystrophy and Huntington’s disease. Wave collaborates with strategic pharmaceutical partners, including GSK, to advance preclinical discovery programs and develop therapeutics addressing both hepatic and extra-hepatic targets.
Company profile, executives and historyWave Life Sciences stock: common questions
What is Wave Life Sciences's stock price?
WVE closed at $3.15 on Nov 12, 2026, down 7.75% on the day. Over the past 52 weeks it traded between $3.04 and $21.73.
What is Wave Life Sciences's market cap?
Wave Life Sciences was worth $622.26M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is WVE's P/E ratio?
Wave Life Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.06), so it has no meaningful P/E ratio.
How much revenue does Wave Life Sciences make?
Wave Life Sciences reported revenue of $70.92M for the twelve months to Sep 30, 2026.
Does Wave Life Sciences pay a dividend?
No. Wave Life Sciences has not paid a cash dividend over the last twelve months.
When does Wave Life Sciences report earnings next?
Wave Life Sciences is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has WVE stock performed over the past year?
Including dividends, WVE returned -54.6% over the past year, against +12.0% for the S&P 500.
How many WVE shares are sold short?
21M shares were sold short at the latest FINRA report, 13.61% of the float, or 6.8 days of average trading volume.
Who are Wave Life Sciences's competitors?
Companies most similar to Wave Life Sciences by business, industry and size include AMLX, STOK, QURE, SEPN, PRTA.
See a number that looks wrong?